Carine Ciron

Nantes, 44200, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

XON9-A Glyco-Humanized Polyclonal Antibody Effective Against Hepatocellular Carcinoma.

XON9-A Glyco-Humanized Polyclonal Antibody Effective Against Hepatocellular Carcinoma.

Journal: International journal of molecular sciences

Published: May 28, 2025

Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants.

Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants.

Journal: Frontiers in immunology

Published: April 19, 2023

LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ transplantation.

LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ transplantation.

Journal: Frontiers in immunology

Published: January 04, 2023

Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors.

Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors.

Journal: JCI insight

Published: October 20, 2022

XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.

XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.

Journal: Frontiers in immunology

Published: August 19, 2021

High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.

High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.

Journal: bioRxiv : the preprint server for biology

Published: May 20, 2021

High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.

High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.

Journal: European journal of immunology

Published: November 17, 2020

Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?

Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?

Journal: Molecular therapy. Methods & clinical development

Published: March 10, 2020

Satellite cells fail to contribute to muscle repair but are functional in Pompe disease (glycogenosis type II).

Satellite cells fail to contribute to muscle repair but are functional in Pompe disease (glycogenosis type II).

Journal: Acta neuropathologica communications

Published: August 17, 2018

Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease.

Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease.

Journal: Acta neuropathologica communications

Published: July 21, 2017

Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders.

Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders.

Journal: Gene therapy

Published: November 11, 2016

PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein.

PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein.

Journal: Acta neuropathologica communications

Published: January 30, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026